Accro Bioscience Secures $50M Series C to Advance RIPK2 Inhibitor AC-101 into Phase IIb Ulcerative Colitis Trial
Accro Bioscience (Suzhou) Limited announced the completion of a $50 million Series C financing round,...
Accro Bioscience (Suzhou) Limited announced the completion of a $50 million Series C financing round,...
Full-Life Technologies announced the successful completion of a $150 million financing round, comprising $110 million...
Bristol-Myers Squibb (BMS) (NYSE: BMY) announced a strategic partnership with the Tigerlily Foundation, a leading...
Allogene Therapeutics, Inc. (NASDAQ: ALLO) announced the termination of its strategic collaboration with Overland Pharmaceuticals...
Eli Lilly and Company (NYSE: LLY) announced a strategic alliance with UNICEF USA this week,...
TenNor Therapeutics (Suzhou) Limited completed its initial public offering (IPO) on the Hong Kong Stock...
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196) announced a strategic licensing agreement with South...
Merck & Co., Inc. (MSD; NYSE: MRK) has established separate strategic partnerships with four leading...
Shanghai Immunocan Biotech Co., Ltd. announced the successful completion of a RMB 250 million (USD...
Shenzhen Weiguang Biological Products Co., Ltd. (SHE: 002880), a China-based blood products manufacturer, announced plans...
Cellular Intelligence announced on May 11, 2026, that it has acquired global rights to Novo...
Boehringer Ingelheim (“BI”) and Immunitas Therapeutics announced on May 12, 2026, a global licensing agreement...
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760), the globally leading medical device innovator, announced...
Akari Therapeutics (NASDAQ: AKTX), the US-UK dual-headquartered biotechnology company, announced a strategic development partnership with...
China Medical System Holdings Limited (CMS, HKG: 0867) announced an exclusive licensing agreement with Denmark-based...
Yifan Pharmaceutical Co., Ltd. (SHE: 002019) announced a licensing agreement with Intsel Chimos SAS, the...
Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced an expanded strategic partnership with Torrent Pharmaceuticals Inc.,...
Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced a strategic licensing agreement with MCG Pharma, the...
Tortugas Neuroscience, a clinical-stage biotechnology company focused on central nervous system (CNS) disorders, announced the...
Zhejiang Shapuaisi Pharmaceutical Co., Ltd. (SHA: 603168) announced it has entered into a comprehensive technology...